The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement.
 
Elena Fountzilas
No Relationships to Disclose
 
Elangovan Krishnan
No Relationships to Disclose
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Immunome; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; BioMed Valley Discoveries; Deciphera; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution
Other Relationship - Bio-Rad
 
Siqing Fu
No Relationships to Disclose
 
Daniel D. Karp
Consulting or Advisory Role - Black Beret Life Sciences
Research Funding - Phosplatin Therapeutics
Travel, Accommodations, Expenses - Phosplatin Therapeutics
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; MedImmune; Merck; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Genentech
Research Funding - Abbvie; Bayer; BlueLink; Curis; Five Prime Therapeutics; GlaxoSmithKline; Helix BioPharma; Incyte; MedImmune; Medivation; Merck Sharp & Dohme; Novartis; Pfizer; Pieris Pharmaceuticals; Principa Biopharma; Puma Biotechnology; Tesaro; XuanZhu
 
David J Vining
Leadership - VisionSR
Stock and Other Ownership Interests - VisionSR
Patents, Royalties, Other Intellectual Property - Bracco Diagnostics, Inc.; VisionSR, Inc
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Roche
Research Funding - Baxter (Inst); Bayer (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Foundation Medicine (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); ONYX (Inst); Placon (Inst); Stem Cells, Inc. (Inst)